- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00381706
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving more than one chemotherapy drug (combination chemotherapy) together with cetuximab may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying three different combination chemotherapy regimens to compare how well they work when given together with cetuximab in treating patients with metastatic esophageal cancer or gastroesophageal junction cancer.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to histology (squamous cell carcinoma vs adenocarcinoma) and Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1 vs 2). Patients are randomized to 1 of 3 treatment arms. For more information please see the "Arms" section which includes a detailed description of the treatment regimens.
The primary objective of the study is evaluate the tumor response rate (RR) for each of the regimens in this trial and to select the most promising regimen based on RR for further testing in patients with metastatic esophageal or GE junction adenocarcinoma. The secondary objectives are:
- To evaluate overall survival (OS) for each of the regimens in this trial in patients with metastatic esophageal or GE junction adenocarcinoma.
- To evaluate progression-free survival (PFS) for each of the regimens in this trial in patients with metastatic esophageal or GE junction adenocarcinoma.
- To evaluate time to treatment failure (TTF) for each of the regimens in this trial in patients with metastatic esophageal or GE junction adenocarcinoma.
- To determine the type and severity of toxicities associated with each of these regimens in the multi-institutional phase II setting.
- Quantitative immunohistochemistry results will be correlated with objective response rate, overall survival and time to progression.
- To evaluate the cellular damage (apoptosis) as a result of oxaliplatin.
- To determine if germline EGFR variants correlate with skin rash in patients treated with cetuximab.
- To evaluate if a correlation exists between germline EGFR variants and tumor EFGR expression as measured by immunohistochemistry.
All subjects must be premedicated with diphenhydramine hydrochloride 50 mg IV (or a similar agent) prior to the first dose of cetuximab in an effort to minimize infusion and hypersensitivity reactions. Premedication is recommended prior to subsequent doses, but the dose of diphenhydramine (or similar agent) may be reduced at the investigator's discretion. More information is detailed in the protocol including a description of the premedication requirements. Patients were closely monitored for treatment-related adverse events. After completion of study treatment, patients are followed periodically for up to 2 years.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Connecticut
-
Norwalk, Connecticut, Spojené státy, 06856
- Norwalk Hospital
-
-
Delaware
-
Lewes, Delaware, Spojené státy, 19958
- Tunnell Cancer Center at Beebe Medical Center
-
Newark, Delaware, Spojené státy, 19713
- CCOP - Christiana Care Health Services
-
-
District of Columbia
-
Washington, District of Columbia, Spojené státy, 20007
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
-
-
Illinois
-
Aurora, Illinois, Spojené státy, 60504
- Rush-Copley Cancer Care Center
-
Bloomington, Illinois, Spojené státy, 61701
- St. Joseph Medical Center
-
Canton, Illinois, Spojené státy, 61520
- Graham Hospital
-
Carthage, Illinois, Spojené státy, 62321
- Memorial Hospital
-
Chicago, Illinois, Spojené státy, 60637-1470
- University of Chicago Cancer Research Center
-
Decatur, Illinois, Spojené státy, 62526
- Decatur Memorial Hospital Cancer Care Institute
-
Eureka, Illinois, Spojené státy, 61530
- Eureka Community Hospital
-
Evanston, Illinois, Spojené státy, 60201-1781
- Evanston Hospital
-
Galesburg, Illinois, Spojené státy, 61401
- Galesburg Cottage Hospital
-
Galesburg, Illinois, Spojené státy, 61401
- Galesburg Clinic, PC
-
Harvey, Illinois, Spojené státy, 60426
- Ingalls Cancer Care Center at Ingalls Memorial Hospital
-
Havana, Illinois, Spojené státy, 62644
- Mason District Hospital
-
Hopedale, Illinois, Spojené státy, 61747
- Hopedale Medical Complex
-
Joliet, Illinois, Spojené státy, 60435
- Joliet Oncology-Hematology Associates, Limited - West
-
Macomb, Illinois, Spojené státy, 61455
- Mcdonough District Hospital
-
Normal, Illinois, Spojené státy, 61761
- Bromenn Regional Medical Center
-
Normal, Illinois, Spojené státy, 61761
- Community Cancer Center
-
Ottawa, Illinois, Spojené státy, 61350
- Community Hospital of Ottawa
-
Ottawa, Illinois, Spojené státy, 61350
- Oncology Hematology Associates of Central Illinois, PC - Ottawa
-
Pekin, Illinois, Spojené státy, 61554
- Cancer Treatment Center at Pekin Hospital
-
Peoria, Illinois, Spojené státy, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Spojené státy, 61614
- Proctor Hospital
-
Peoria, Illinois, Spojené státy, 61637
- OSF St. Francis Medical Center
-
Peoria, Illinois, Spojené státy, 61615
- CCOP - Illinois Oncology Research Association
-
Peoria, Illinois, Spojené státy, 61615
- Oncology Hematology Associates of Central Illinois, PC - Peoria
-
Peru, Illinois, Spojené státy, 61354
- Illinois Valley Community Hospital
-
Princeton, Illinois, Spojené státy, 61356
- Perry Memorial Hospital
-
Rockford, Illinois, Spojené státy, 61104-2315
- Swedish-American Regional Cancer Center
-
Spring Valley, Illinois, Spojené státy, 61362
- St. Margaret's Hospital
-
Springfield, Illinois, Spojené státy, 62781-0001
- Regional Cancer Center at Memorial Medical Center
-
Urbana, Illinois, Spojené státy, 61801
- Carle Cancer Center at Carle Foundation Hospital
-
Urbana, Illinois, Spojené státy, 61801
- CCOP - Carle Cancer Center
-
-
Indiana
-
Elkhart, Indiana, Spojené státy, 46515
- Elkhart General Hospital
-
Fort Wayne, Indiana, Spojené státy, 46845
- Fort Wayne Medical Oncology and Hematology
-
Indianapolis, Indiana, Spojené státy, 46202-5289
- Indiana University Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Spojené státy, 46202
- William N. Wishard Memorial Hospital
-
Kokomo, Indiana, Spojené státy, 46904
- Howard Community Hospital
-
La Porte, Indiana, Spojené státy, 46350
- Center for Cancer Therapy at LaPorte Hospital and Health Services
-
Michigan City, Indiana, Spojené státy, 46360
- Saint Anthony Memorial Health Centers
-
South Bend, Indiana, Spojené státy, 46601
- Memorial Hospital of South Bend
-
South Bend, Indiana, Spojené státy, 46601
- CCOP - Northern Indiana CR Consortium
-
South Bend, Indiana, Spojené státy, 46617
- Saint Joseph Regional Medical Center
-
South Bend, Indiana, Spojené státy, 46617
- South Bend Clinic
-
-
Iowa
-
Ames, Iowa, Spojené státy, 50010
- McFarland Clinic, PC
-
Bettendorf, Iowa, Spojené státy, 52722
- Hematology Oncology Associates of the Quad Cities
-
Cedar Rapids, Iowa, Spojené státy, 52403
- Cedar Rapids Oncology Associates
-
Cedar Rapids, Iowa, Spojené státy, 52403
- Mercy Regional Cancer Center at Mercy Medical Center
-
Des Moines, Iowa, Spojené státy, 50309
- CCOP - Iowa Oncology Research Association
-
Des Moines, Iowa, Spojené státy, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, Spojené státy, 50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines, Iowa, Spojené státy, 50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines, Iowa, Spojené státy, 50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Spojené státy, 50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Des Moines, Iowa, Spojené státy, 50307
- Mercy Capitol Hospital
-
Iowa City, Iowa, Spojené státy, 52242-1002
- Holden Comprehensive Cancer Center at University of Iowa
-
Mason City, Iowa, Spojené státy, 50401
- Mercy Cancer Center at Mercy Medical Center - North Iowa
-
Ottumwa, Iowa, Spojené státy, 52501
- McCreery Cancer Center at Ottumwa Regional
-
Sioux City, Iowa, Spojené státy, 51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City, Iowa, Spojené státy, 51104
- St. Luke's Regional Medical Center
-
Sioux City, Iowa, Spojené státy, 51104
- Mercy Medical Center - Sioux City
-
West Des Moines, Iowa, Spojené státy, 50266
- Medical Oncology and Hematology Associates - West Des Moines
-
-
Kansas
-
Anthony, Kansas, Spojené státy, 67003
- Hospital District Sixth of Harper County
-
Chanute, Kansas, Spojené státy, 66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City, Kansas, Spojené státy, 67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado, Kansas, Spojené státy, 67042
- Cancer Center of Kansas, PA - El Dorado
-
Fort Scott, Kansas, Spojené státy, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Spojené státy, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, Spojené státy, 67068
- Cancer Center of Kansas, PA - Kingman
-
Lawrence, Kansas, Spojené státy, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Spojené státy, 67901
- Southwest Medical Center
-
Newton, Kansas, Spojené státy, 67114
- Cancer Center of Kansas, PA - Newton
-
Overland Park, Kansas, Spojené státy, 66209
- Menorah Medical Center
-
Parsons, Kansas, Spojené státy, 67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt, Kansas, Spojené státy, 67124
- Cancer Center of Kansas, PA - Pratt
-
Salina, Kansas, Spojené státy, 67042
- Cancer Center of Kansas, PA - Salina
-
Shawnee Mission, Kansas, Spojené státy, 66204
- Shawnee Mission Medical Center
-
Wellington, Kansas, Spojené státy, 67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita, Kansas, Spojené státy, 67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita, Kansas, Spojené státy, 67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita, Kansas, Spojené státy, 67214
- CCOP - Wichita
-
Wichita, Kansas, Spojené státy, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita, Kansas, Spojené státy, 67208
- Associates in Womens Health, PA - North Review
-
Winfield, Kansas, Spojené státy, 67156
- Cancer Center of Kansas, PA - Winfield
-
-
Maine
-
Bangor, Maine, Spojené státy, 04401
- CancerCare of Maine at Eastern Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21237
- Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center
-
Easton, Maryland, Spojené státy, 21601
- Shore Regional Cancer Center at Memorial Hospital - Easton
-
Elkton, Maryland, Spojené státy, 21921
- Union Hospital of Cecil County
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Spojené státy, 02115
- Dana-Farber/Brigham and Women's Cancer Center
-
Boston, Massachusetts, Spojené státy, 02115
- Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
-
Burlington, Massachusetts, Spojené státy, 01805
- Lahey Clinic Medical Center - Burlington
-
South Weymouth, Massachusetts, Spojené státy, 02190
- South Shore Hospital
-
Springfield, Massachusetts, Spojené státy, 01199
- Baystate Regional Cancer Program at D'Amour Center for Cancer Care
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor, Michigan, Spojené státy, 48106
- CCOP - Michigan Cancer Research Consortium
-
Dearborn, Michigan, Spojené státy, 48123-2500
- Oakwood Cancer Center at Oakwood Hospital and Medical Center
-
Escanaba, Michigan, Spojené státy, 49431
- Green Bay Oncology, Limited - Escanaba
-
Flint, Michigan, Spojené státy, 48503
- Hurley Medical Center
-
Flint, Michigan, Spojené státy, 48503
- Genesys Hurley Cancer Institute
-
Grosse Pointe Woods, Michigan, Spojené státy, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Iron Mountain, Michigan, Spojené státy, 49801
- Dickinson County Healthcare System
-
Jackson, Michigan, Spojené státy, 49201
- Foote Memorial Hospital
-
Kalamazoo, Michigan, Spojené státy, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Spojené státy, 49001
- Borgess Medical Center
-
Kalamazoo, Michigan, Spojené státy, 49007-3731
- West Michigan Cancer Center
-
Lansing, Michigan, Spojené státy, 48912-1811
- Sparrow Regional Cancer Center
-
Livonia, Michigan, Spojené státy, 48154
- St. Mary Mercy Hospital
-
Pontiac, Michigan, Spojené státy, 48341-2985
- St. Joseph Mercy Oakland
-
Port Huron, Michigan, Spojené státy, 48060
- Mercy Regional Cancer Center at Mercy Hospital
-
Saginaw, Michigan, Spojené státy, 48601
- Seton Cancer Institute at Saint Mary's - Saginaw
-
Saint Joseph, Michigan, Spojené státy, 49085
- Lakeland Regional Cancer Care Center - St. Joseph
-
Saint Joseph, Michigan, Spojené státy, 49085
- Oncology Care Associates, PLLC
-
Warren, Michigan, Spojené státy, 48093
- St. John Macomb Hospital
-
-
Minnesota
-
Burnsville, Minnesota, Spojené státy, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Spojené státy, 55433
- Mercy and Unity Cancer Center at Mercy Hospital
-
Duluth, Minnesota, Spojené státy, 55805
- CCOP - Duluth
-
Duluth, Minnesota, Spojené státy, 55805
- Miller - Dwan Medical Center
-
Duluth, Minnesota, Spojené státy, 55805-1983
- Essentia Health - Duluth Clinic
-
Edina, Minnesota, Spojené státy, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Spojené státy, 55432
- Mercy and Unity Cancer Center at Unity Hospital
-
Hutchinson, Minnesota, Spojené státy, 55350
- Hutchinson Area Health Care
-
Litchfield, Minnesota, Spojené státy, 55355
- Meeker County Memorial Hospital
-
Maplewood, Minnesota, Spojené státy, 55109
- HealthEast Cancer Care at St. John's Hospital
-
Maplewood, Minnesota, Spojené státy, 55109
- Minnesota Oncology - Maplewood
-
Minneapolis, Minnesota, Spojené státy, 55417
- Veterans Affairs Medical Center - Minneapolis
-
Minneapolis, Minnesota, Spojené státy, 55407
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
-
Minneapolis, Minnesota, Spojené státy, 55415
- Hennepin County Medical Center - Minneapolis
-
Robbinsdale, Minnesota, Spojené státy, 55422-2900
- Humphrey Cancer Center at North Memorial Outpatient Center
-
Saint Louis Park, Minnesota, Spojené státy, 55416
- CCOP - Metro-Minnesota
-
Saint Louis Park, Minnesota, Spojené státy, 55416
- Park Nicollet Cancer Center
-
Saint Paul, Minnesota, Spojené státy, 55102
- United Hospital
-
Saint Paul, Minnesota, Spojené státy, 55101
- Regions Hospital Cancer Care Center
-
Shakopee, Minnesota, Spojené státy, 55379
- St. Francis Cancer Center at St. Francis Medical Center
-
Waconia, Minnesota, Spojené státy, 55387
- Ridgeview Medical Center
-
Woodbury, Minnesota, Spojené státy, 55125
- Minnesota Oncology - Woodbury
-
-
Missouri
-
Independence, Missouri, Spojené státy, 64050
- Independence Regional Health Center
-
Kansas City, Missouri, Spojené státy, 64131
- CCOP - Kansas City
-
Kansas City, Missouri, Spojené státy, 64116
- North Kansas City Hospital
-
Kansas City, Missouri, Spojené státy, 64132
- Research Medical Center
-
Kansas City, Missouri, Spojené státy, 64108
- Truman Medical Center - Hospital Hill
-
Kansas City, Missouri, Spojené státy, 64111
- Saint Luke's Cancer Institute at Saint Luke's Hospital
-
Kansas City, Missouri, Spojené státy, 64114
- St. Joseph Medical Center
-
Kansas City, Missouri, Spojené státy, 64116
- Parvin Radiation Oncology
-
Liberty, Missouri, Spojené státy, 64068
- Liberty Hospital
-
Saint Joseph, Missouri, Spojené státy, 64506
- Heartland Regional Medical Center
-
Saint Louis, Missouri, Spojené státy, 63131
- Missouri Baptist Cancer Center
-
Saint Louis, Missouri, Spojené státy, 63141
- Arch Medical Services, Incorporated at Center for Cancer Care and Research
-
-
Nebraska
-
Omaha, Nebraska, Spojené státy, 68106
- CCOP - Missouri Valley Cancer Consortium
-
Omaha, Nebraska, Spojené státy, 68122
- Immanuel Medical Center
-
Omaha, Nebraska, Spojené státy, 68124
- Alegant Health Cancer Center at Bergan Mercy Medical Center
-
Omaha, Nebraska, Spojené státy, 68131-2197
- Creighton University Medical Center
-
Omaha, Nebraska, Spojené státy, 68114
- Methodist Estabrook Cancer Center
-
-
Nevada
-
Las Vegas, Nevada, Spojené státy, 89102
- University Medical Center of Southern Nevada
-
Las Vegas, Nevada, Spojené státy, 89106
- CCOP - Nevada Cancer Research Foundation
-
-
New Hampshire
-
Lebanon, New Hampshire, Spojené státy, 03756-0002
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Marlton, New Jersey, Spojené státy, 08053
- Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
-
Newark, New Jersey, Spojené státy, 07112
- Newark Beth Israel Medical Center
-
Sparta, New Jersey, Spojené státy, 07871
- Frederick R. and Betty M. Smith Cancer Treatment Center
-
Voorhees, New Jersey, Spojené státy, 08043
- Cancer Institute of New Jersey at Cooper - Voorhees
-
Voorhees, New Jersey, Spojené státy, 08043
- Fox Chase Virtua Health Cancer Program at Virtua West Jersey
-
-
New York
-
Bronx, New York, Spojené státy, 10466
- Our Lady of Mercy Medical Center Comprehensive Cancer Center
-
Buffalo, New York, Spojené státy, 14215
- Veterans Affairs Medical Center - Buffalo
-
East Syracuse, New York, Spojené státy, 13057
- CCOP - Hematology-Oncology Associates of Central New York
-
Glens Falls, New York, Spojené státy, 12801
- Charles R. Wood Cancer Center at Glens Falls Hospital
-
New York, New York, Spojené státy, 10065
- Memorial Sloan-Kettering Cancer Center
-
New York, New York, Spojené státy, 10035
- Ralph Lauren Center for Cancer Care and Prevention
-
-
North Carolina
-
Chapel Hill, North Carolina, Spojené státy, 27599-7295
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
-
Charlotte, North Carolina, Spojené státy, 28232-2861
- Blumenthal Cancer Center at Carolinas Medical Center
-
Goldsboro, North Carolina, Spojené státy, 27534
- Wayne Memorial Hospital, Incorporated
-
Hendersonville, North Carolina, Spojené státy, 28791
- Pardee Memorial Hospital
-
Kinston, North Carolina, Spojené státy, 28501
- Kinston Medical Specialists
-
-
Ohio
-
Akron, Ohio, Spojené státy, 44309-2090
- Summa Center for Cancer Care at Akron City Hospital
-
Canton, Ohio, Spojené státy, 44710-1799
- Aultman Cancer Center at Aultman Hospital
-
Cleveland, Ohio, Spojené státy, 44109
- MetroHealth Cancer Care Center at MetroHealth Medical Center
-
Columbus, Ohio, Spojené státy, 43210-1240
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
-
Lima, Ohio, Spojené státy, 45801
- St. Rita's Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Spojené státy, 18105
- Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
-
Bethlehem, Pennsylvania, Spojené státy, 18015
- St. Luke's Cancer Network at St. Luke's Hospital
-
Danville, Pennsylvania, Spojené státy, 17822-0001
- Geisinger Cancer Institute at Geisinger Health
-
East Stroudsburg, Pennsylvania, Spojené státy, 18301
- Dale and Frances Hughes Cancer Center at Pocono Medical Center
-
Hazleton, Pennsylvania, Spojené státy, 18201
- Geisinger Hazleton Cancer Center
-
Hershey, Pennsylvania, Spojené státy, 17033-0850
- Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center
-
Lewistown, Pennsylvania, Spojené státy, 17044
- Lewistown Hospital
-
Philadelphia, Pennsylvania, Spojené státy, 19111-2497
- Fox Chase Cancer Center - Philadelphia
-
Philadelphia, Pennsylvania, Spojené státy, 19104-4283
- Abramson Cancer Center of the University of Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19107-5541
- Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
-
Philadelphia, Pennsylvania, Spojené státy, 19107
- Joan Karnell Cancer Center at Pennsylvania Hospital
-
Philadelphia, Pennsylvania, Spojené státy, 19114
- Frankford Hospital Cancer Center - Torresdale Campus
-
Scranton, Pennsylvania, Spojené státy, 18508
- Hematology and Oncology Associates of Northeastern Pennsylvania
-
State College, Pennsylvania, Spojené státy, 16803
- Mount Nittany Medical Center
-
State College, Pennsylvania, Spojené státy, 16801
- Geisinger Medical Group - Scenery Park
-
Wilkes-Barre, Pennsylvania, Spojené státy, 18711
- Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
-
Wilkes-Barre, Pennsylvania, Spojené státy, 18765
- Mercy Hospital at Wilkes-Barre
-
Williamsport, Pennsylvania, Spojené státy, 17701
- Susquehanna Cancer Center at Divine Providence Hospital
-
-
South Carolina
-
Florence, South Carolina, Spojené státy, 29501
- McLeod Regional Medical Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Spojené státy, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Spojené státy, 57105
- Medical X-Ray Center, PC
-
Sioux Falls, South Dakota, Spojené státy, 57117-5039
- Sanford Cancer Center at Sanford USD Medical Center
-
-
Tennessee
-
Kingsport, Tennessee, Spojené státy, 37662
- Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center
-
-
Texas
-
Temple, Texas, Spojené státy, 76508
- CCOP - Scott and White Hospital
-
-
Vermont
-
Berlin, Vermont, Spojené státy, 05602
- Mountainview Medical
-
Burlington, Vermont, Spojené státy, 05401
- Fletcher Allen Health Care - University Health Center Campus
-
-
Virginia
-
Danville, Virginia, Spojené státy, 24541
- Danville Regional Medical Center
-
Norton, Virginia, Spojené státy, 24273
- Southwest Virginia Regional Cancer Center at Wellmonth Health
-
-
Wisconsin
-
Eau Claire, Wisconsin, Spojené státy, 54701
- Center for Cancer Treatment & Prevention at Sacred Heart Hospital
-
Eau Claire, Wisconsin, Spojené státy, 54701
- Marshfield Clinic Cancer Care at Regional Cancer Center
-
Green Bay, Wisconsin, Spojené státy, 54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, Spojené státy, 54301-3526
- Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, Spojené státy, 54303
- Green Bay Oncology, Limited at St. Mary's Hospital
-
Green Bay, Wisconsin, Spojené státy, 54303
- St. Mary's Hospital Medical Center - Green Bay
-
Marinette, Wisconsin, Spojené státy, 54143
- Bay Area Cancer Care Center at Bay Area Medical Center
-
Marshfield, Wisconsin, Spojené státy, 54449
- Saint Joseph's Hospital
-
Milwaukee, Wisconsin, Spojené státy, 53215
- Medical Consultants, Limited
-
Minocqua, Wisconsin, Spojené státy, 54548
- Marshfield Clinic - Lakeland Center
-
Oconto Falls, Wisconsin, Spojené státy, 54154
- Green Bay Oncology, Limited - Oconto Falls
-
Rhinelander, Wisconsin, Spojené státy, 54501
- Ministry Medical Group at Saint Mary's Hospital
-
Rice Lake, Wisconsin, Spojené státy, 54868
- Marshfield Clinic - Indianhead Center
-
Stevens Point, Wisconsin, Spojené státy, 54481
- Saint Michael's Hospital Cancer Center
-
Sturgeon Bay, Wisconsin, Spojené státy, 54235
- Green Bay Oncology, Limited - Sturgeon Bay
-
Wausau, Wisconsin, Spojené státy, 54401
- Marshfield Clinic - Wausau Center
-
Wausau, Wisconsin, Spojené státy, 54401
- University of Wisconcin Cancer Center at Aspirus Wausau Hospital
-
Weston, Wisconsin, Spojené státy, 54476
- Marshfield Clinic - Weston Center
-
Wisconsin Rapids, Wisconsin, Spojené státy, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Metastatic disease of the esophagus or gastroesophageal junction
- Histologic, cytologic or radiologic documentation of metastatic squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal junction. Radiologic, endoscopic, histologic or cytologic evidence of locally recurrent or locally residual (post-resection) disease is also permitted.
- For the purposes of this study, undifferentiated adenocarcinomas and adenosquamous tumors will be considered as adenocarcinomas. In addition, tumors involving the gastroesophageal junction will be defined by the Siewert classification.
Patients with gastroesophageal junction tumors who are eligible:
- AEG Type I: Adenocarcinoma of the distal esophagus which usually arises from an area with specialized intestinal metaplasia of the esophagus (eg, Barrett's esophagus, and may infiltrate the esophagogastric junction from above).
- AEG Type II: True carcinoma of the cardia arising from the cardiac epithelium or short segments with intestinal metaplasia at the esophagogastric junction.
Patients with gastroesophageal junction tumors who are NOT eligible:
- AEG Type III: Subcardial gastric carcinoma which infiltrates the esophagogastric junction and distal esophagus from below.
Patients must have at least one paraffin block available (or at least 15 unstained slides for analysis of tumor EGFR status.
- Patients with a history of esophageal and GE junction carcinoma treated by surgical resection who develop radiological or clinical evidence of metastatic cancer do not require separate histological or cytological confirmation of metastatic disease unless an interval of greater than five years has elapsed between the primary surgery and the development of metastatic disease OR the primary cancer was stage I.
- Clinicians should consider biopsy of lesions to establish the diagnosis of metastatic esophageal or GE junction carcinoma if there is substantial clinical ambiguity regarding the nature or source of apparent metastases.
- Patients with Measurable Disease - Lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan.
Prior Treatment:
- No prior chemotherapy or radiotherapy. No prior therapy which specifically and directly targets the EGF(R) pathway.
- No prior allergic reaction to chimerized or murine monoclonal antibody therapy or documented presence of human anti-mouse antibodies (HAMA).
- Patients must have completed any major surgery ≥ 4 weeks or any minor surgery ≥ 2 weeks before registration. Patients must have fully recovered from the procedure. Insertion of a vascular access device is not considered major or minor surgery.
- No concurrent use of investigational agents is allowed while participating in this study.
Patient Characteristics:
- ECOG Performance Status of 0-2
- ≥ 18 years of age
- Patients must be documented to have a stable weight (or less than one pound weight loss) for at least one week prior to registration.
- Non-pregnant and not breast-feeding. The effects of cetuximab, cisplatin, epirubicin, fluorouracil, leucovorin, irinotecan, and oxaliplatin on a developing human fetus are not well-known. Because the risk of toxicity in nursing infants secondary to cetuximab, cisplatin, epirubicin, fluorouracil, irinotecan, and oxaliplatin treatment of the mother is unknown but may be harmful, breastfeeding must be discontinued.
- No myocardial infarction < 6 months prior to registration or New York Heart Association classification III or IV.
- No ≥ grade 2 diarrhea within 7 days prior to registration.
Patients may not concurrently have any of the following conditions:
- Known central nervous system metastases or carcinomatous meningitis
- Interstitial pneumonia or symptomatic interstitial fibrosis of the lung
- Seizure disorder or active neurological disease requiring anti-epileptic medication
- ≥ grade 2 peripheral neuropathy
- No evidence of Gilbert's Syndrome - Patients with Gilbert's Syndrome may have a greater risk of irinotecan toxicity due to the abnormal glucuronidation of SN-38, the active metabolite of irinotecan. Evidence of Gilbert's Syndrome would include documentation of elevation of indirect bilirubin at any time in the patient's medical history.
Required Initial Laboratory Data:
- Granulocytes ≥ 1500/µl
- Platelet count ≥ 100,000/µl
- Creatinine ≤ 1.5 mg/dL
- AST (SGOT) ≤ 5.0 x Upper limits of normal
- Total bilirubin ≤ 1.5 mg/dL
- Albumin ≥ 2.5 grams/dL
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Arm A (ECF + cetuximab)
Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter.
Patients receive cetuximab IV on days 1, 8 and 15.
Patients receive epirubicin 50 mg/m^2 IV after cetuximab on day 1 followed by cisplatin 60 mg/m^2 IV over 60 minutes.
On days 1-21, patients receive 5-fluorouracil 200 mg/m^2/day continuous IV infusion.
Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
|
daný IV
Ostatní jména:
epirubicin and 5-fluorouracil given IV
Ostatní jména:
|
|
Experimentální: Arm B (IC + cetuximab)
Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter.
Patients receive cetuximab on days 1, 8 and 15.
Patients receive cisplatin 30 mg/m^2 IV over 30 minutes on days 1 and 8 after cetuximab.
Patients also receive irinotecan 65 mg/m^2 IV over 90 minutes on days 1 and 8 after receiving cisplatin.Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
|
daný IV
Ostatní jména:
cisplatin and irinotecan given IV
Ostatní jména:
|
|
Experimentální: ARM C (FOLFOX + cetuximab)
Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter.
Patients receive cetuximab on days 1 and 8. On Day 1, patients also receive oxaliplatin 85 mg/m^2 IV over 120 minutes and leucovorin 400 mg/m^2 IV over 120 minutes either concurrently with oxaliplatin via a separate infusion line or post oxaliplatin administration.
Following leucovorin, patients will receive 5-fluorouracil 400 mg/m^2 IV bolus injection, then 5-fluorouracil 2400 mg/m^2 IV infusion over 46-48 hours.
Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
|
daný IV
Ostatní jména:
oxaliplatin , leucovorin and 5-fluorouracil IV
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Response Rate (Complete and Partial) in Patients With Measurable Esophageal or GE Junction Adenocarcinoma
Časové okno: Up to 2 years post-treatment
|
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria.
Overall tumor response is the total number of CR and PRs in participants with adenocarcinoma who have received at least one cycle of therapy.
|
Up to 2 years post-treatment
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Tumor Response Rate (Complete and Partial) in Patients With Squamous Cell Carcinoma
Časové okno: Up to 2 years post-treatment
|
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria.
Overall tumor response is the total number of CR and PRs in participants with squamous cell carcinoma who have received at least one cycle of therapy.
|
Up to 2 years post-treatment
|
|
Overall Survival in Patients With Adenocarcinoma
Časové okno: Up to 2 years post-treatment
|
Overall survival (OS) was defined as the time from study entry to death of any cause.
The median OS with 95% CI was estimated using the Kaplan Meier method.
|
Up to 2 years post-treatment
|
|
Progression-free Survival in Patients With Adenocarcinoma
Časové okno: Up to 2 years post-treatment
|
Progression free survival (PFS) was defined as the time from study entry to progression or death of any cause.
The median PFS with 95% CI was estimated using the Kaplan Meier method.
|
Up to 2 years post-treatment
|
|
Time to Treatment Failure in Patients With Adenocarcinoma
Časové okno: Up to 2 years post-treatment
|
Time to treatment failure (TTF) was measured from study entry until documented progression, death resulting from any cause, or end of protocol therapy because of unacceptable toxicity.
The median TTF with 95% CI was estimated using the Kaplan Meier method.
|
Up to 2 years post-treatment
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Vyšetřovatelé
- Studijní židle: Peter Enzinger, MD, Dana-Farber Cancer Institute
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Nemoci trávicího systému
- Novotvary
- Novotvary podle místa
- Gastrointestinální novotvary
- Novotvary trávicího systému
- Gastrointestinální onemocnění
- Novotvary hlavy a krku
- Nemoci jícnu
- Novotvary jícnu
- Fyziologické účinky léků
- Molekulární mechanismy farmakologického působení
- Inhibitory enzymů
- Antimetabolity, Antineoplastika
- Antimetabolity
- Antineoplastická činidla
- Imunosupresivní látky
- Imunologické faktory
- Ochranné prostředky
- Inhibitory topoizomerázy II
- Inhibitory topoizomerázy
- Antineoplastická činidla, Imunologická
- Mikroživiny
- Antibiotika, antineoplastika
- Vitamíny
- Inhibitory topoizomerázy I
- Protijedy
- Vitamín B komplex
- Cisplatina
- Fluorouracil
- Epirubicin
- Oxaliplatina
- Leukovorin
- Irinotekan
- Cetuximab
Další identifikační čísla studie
- CALGB-80403
- ECOG-E1206
- CDR0000505535 (Jiný identifikátor: Physician Data Query)
- NCI-2009-00492 (Jiný identifikátor: NCI Clinical Trial Reporting Program)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .